HPAPI (High Potency Active Pharmaceutical Ingredients) Global Market

Forecast to 2023

HPAPI (High Potency Active Pharmaceutical Ingredients) Global Market is

estimated to be worth $27,293.4 million by 2023

IQ4I Research & Consultancy published a new report on HPAPI Global Market
Forecast To 2023 This report analyzes and studies the overall market, major Drivers &
Opportunities, Restraints & Threats in North America, Europe, Asia-Pacific and Rest of the
World

IQ4Is Report Contains 63 market data tables and 60 figures spread through 226 pages and
an exhaustive TOC on HPAPI Global Market, CUSTOMER BASE (Innovative HPAPI, Generic
HPAPI); BUSINESS TYPE(Captive HPAPI, Merchant HPAPI); MOLECULE TYPE (Synthetic
HPAPI, Biotech HPAPI), APPLICATIONS (Oncology, Central Nervous System disorders,
Hormonal disorders, Glaucoma, Infectious diseases, Metabolic disorders, Cardiovascular
disorders, Inflammation and Others); REGIONAL (North America, Europe, Asia Pacific and
Rest of the World)]

The drugs are classified as High Potent if its Occupational Exposure Limit (OELs)
10g/m3. These high potent intermediates are highly selective in nature and works
effectively even with small doses. So they are being increasingly used in many therapeutic
applications such as Cancer, CNS (Central Nervous System) disorders, Hormonal disorders,
Glaucoma, Cardiovascular and metabolic disorders. The HPAPI global market is growing in
terms of revenue and there has been a rise in demand for outsourcing these intermediates
manufacturing is driven by expansion of oncology sector, which is the fastest among overall
pharmaceutical sector, increase in number of ADCs, growing number of CMOs for
manufacturing.

As estimated by IQ4I Research and Consultancy, the HPAPI global market was estimated to
reach $27,293.4 million by 2023 growth at high single digit CAGR. HPAPI market is mainly
classified by customer base, business type, molecule type and Applications. The global
HPAPI market is broadly classified as Innovative HPAPI and Generic HPAPI based on
customer base. Innovative HPAPI holds the maximum share, However, Generic HPAPI are
expected to grow at a strong CAGR because of increase in number of generic HPAPI
manufacturers, increase in government initiatives to use of generic HPAPI drugs, nearing
patent expires (Patent Cliffs) of drugs. Based on business type, the market is classified into
Captive HPAPI & Merchant HPAPI. Captive HPAPI holds the maximum share and Merchant
HPAPI is expected to grow at a strong CAGR. HPAPI market is segmented on the basis of
molecule type as Synthetic HPAPI and Biotech HPAPI. Synthetic HPAPI holds the maximum
share. However, the Biotech HPAPI is expected to grow at a strong CAGR as there is an
increasing focus on research & development of use of these for many therapies. HPAPI

IQ4I Research & Consultancy Pvt. Ltd. Page 1

HPAPI (High Potency Active Pharmaceutical Ingredients) Global Market

Forecast to 2023

market application segment is classified into Oncology, Cardiovascular, Central Nervous

system, Hormonal, Glaucoma, Infectious, metabolic, Inflammation and other therapeutic
applications. Oncology holds the maximum share among applications and estimated to grow
at a strong CAGR.

The HPAPI market is highly fragmented and the major seven players in the market are
Merck KGaA (Germany), Alkermes (Ireland), Lonza Group (Switzerland), Pfizer (U.S.),
Dishman Group (India), Cambrex Corporation (U.S.) and Teva Pharmaceutical Industries
(Israel). Through acquisitions, few larger pharmaceutical companies are trying to enter the
market. For instance, Merck KGaA (Germany) acquired sigma Aldrich in 2015 and thus
entered the HPAPI market and now is the global leader in the market.

Geographically, North America commanded the largest share in the HPAPI global market
and is expected to grow with double digit rate from 2016-2023. The Asia-Pacific region with
emerging countries represents huge growth opportunities for the HPAPI market to flourish.

Major players in HPAPI market include Alkermes plc (Ireland), Cambrex Corporation (U.S.),
Dishman Group (India), Dr. Reddys Laboratories (India), Lonza Group (Switzerland),
Novasep (U.S.), Patheon N.V.(Netherland),(Acquired by ThermoFisher Scientific), Pfizer
(U.S.), Merck KGaA (Germany), Teva Pharmaceutical Industries (Israel).

Other key players in the HPAPI market include Evonik Industries (Germany), Fermion
(Finland), Johnson Matthey (U.K.), Piramal Pharma Solution (India), Stason
Pharmaceuticals (U.S.), Wuxi PharmaTec (China), Catalent Pharma Solutions Inc. (U.S.)

Reasons for buying this report:

Analysis of the HPAPI global market by identifying various segments by Customer
Base, Business Type, Molecule Type, applications and geography.
Revenue forecast of the HPAPI global market and strategic analysis of each
submarket with respect to segmental growth trends.
Analysis of the major market trends and factors driving or inhibiting the growth of the
HPAPI global market.
Revenue forecast of the HPAPI global market with respect to North America (U.S.
and others), Europe (Switzerland, Germany, U.K. and Others), Asia-Pacific (Japan,
China, India and others) and the Rest of the World (RoW) (Brazil, Rest of Latin
America and, Middle East & Others).

IQ4I Research & Consultancy Pvt. Ltd. Page 2

HPAPI (High Potency Active Pharmaceutical Ingredients) Global Market

Forecast to 2023

Analysis of the opportunities for stakeholders by identifying the high-growth

segments of the market.
Country level analysis of each segment.
Identification of key therapeutic application which is driving the market.
Profiles of major players in the HPAPI global market with details of their product
offerings, business strategies, SWOTs, upcoming technology, and supply chain
analysis.
Market share analysis of HPAPI global market.
Established and Emerging players (116 companies) and their product offerings.

IQ4I Research & Consultancy Pvt. Ltd. Page 3

HPAPI (High Potency Active Pharmaceutical Ingredients) Global Market

Forecast to 2023

FIGURE 1

HPAPI GLOBAL MARKET SEGMENTATION

High Potency Active Pharmaceutical Ingredient (HPAPI) Global Market

By Customer
By Business type By Molecule type By applications By Geography
Base

Innovative HPAPI Captive HPAPI Synthetic HPAPI Oncology North America

Generic HPAPI Merchant HPAPI Biotech HPAPI CNS Europe

Hormonal Asia Pacific

Rest of the
Glaucoma
World

Infectious

Metabolic

Cardiovascular

Inflammation

Others

IQ4I Research & Consultancy Pvt. Ltd. Page 4